The beneficial use of mAbs against TNFα has also been demonstrated in ovarian cancer xenografts; treatment of tumor-bearing mice with infliximab twice a week for 4 weeks resulted in reduced tumor burden, a significantly decreased proportion of infiltrating macrophages, and a marked reduction of IL-6 in the TME [191]. Here, TNF is linked to ovarian cancer.